It makes sense and dollars to buy Arrowhead Pharmaceuticals Inc. (ARWR) stock

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) stock jumped 5.57% on Friday to $44.36 against a previous-day closing price of $42.02. With 1.15 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.88 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $45.32 whereas the lowest price it dropped to was $43.47. The 52-week range on ARWR shows that it touched its highest point at $84.83 and its lowest point at $26.81 during that stretch. It currently has a 1-year price target of $76.83. Beta for the stock currently stands at 1.38.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARWR was up-trending over the past week, with a rise of 0.11%, but this was up by 13.28% over a month. Three-month performance surged to 4.01% while six-month performance fell -19.49%. The stock lost -33.54% in the past year, while it has lost -33.09% so far this year. A look at the trailing 12-month EPS for ARWR yields -1.09 with Next year EPS estimates of -1.97. For the next quarter, that number is -0.51. This implies an EPS growth rate of -61.70% for this year and -42.80% for next year. EPS is expected to grow by 7.33% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -0.30%.

Float and Shares Shorts:

At present, 105.55 million ARWR shares are outstanding with a float of 102.93 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.93 million, which was 4.66% higher than short shares on Jun 14, 2022. In addition to Dr. Christopher R. Anzalone Ph.D. as the firm’s CEO, Pres & Director, Mr. Kenneth A. Myszkowski serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 67.02% of ARWR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 42.01% of ARWR, in contrast to 4.14% held by mutual funds. Shares owned by individuals account for 22.71%. As the largest shareholder in ARWR with 10.39% of the stake, BlackRock Fund Advisors holds 10,982,385 shares worth 10,982,385. A second-largest stockholder of ARWR, The Vanguard Group, Inc., holds 9,445,662 shares, controlling over 8.93% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in ARWR, holding 4,681,955 shares or 4.43% stake. With a 2.88% stake in ARWR, the iShares Core S&P Mid Cap ETF is the largest stakeholder. A total of 3,040,755 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.80% of ARWR stock, is the second-largest Mutual Fund holder. It holds 2,958,021 shares valued at 104.15 million. Vanguard Small Cap Index Fund holds 2.40% of the stake in ARWR, owning 2,533,290 shares worth 89.2 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARWR since 10 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARWR analysts setting a high price target of $110.00 and a low target of $35.00, the average target price over the next 12 months is $74.30. Based on these targets, ARWR could surge 147.97% to reach the target high and fall by -21.1% to reach the target low. Reaching the average price target will result in a growth of 67.49% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ARWR will report FY 2022 earnings on 12/13/2022. Analysts have provided yearly estimates in a range of $0.41 being high and -$1.72 being low. For ARWR, this leads to a yearly average estimate of -$1.28. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Arrowhead Pharmaceuticals Inc. surprised analysts by $0.27 when it reported $0.41 EPS against a consensus estimate of $0.14. The surprise factor in the prior quarter was -$0.15. Based on analyst estimates, the high estimate for the next quarter is $0.26 and the low estimate is -$0.88. The average estimate for the next quarter is thus -$0.57.

Summary of Insider Activity:

Insiders traded ARWR stock several times over the past three months with 1 Buys and 1 Sells. In these transactions, 2,501 shares were bought while 551,197 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has risen to 52 over the past year. The total number of shares bought during that period was 1,214,556 while 971,815 shares were sold.

Leave a Comment

Your email address will not be published.